Microarray‐based IgE serology improves management of severe atopic dermatitis in two children

Феденко, Е С; Elisyutina, O G; Shtyrbul, O V; Пампура, А Н; Valenta, Rudolf; Lupinek, Christian; Khaitov, Musa

doi:10.1111/pai.12572

Cited by 19 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Complex cases, such as multiple sensitizations to respiratory and food allergens and idiopathic anaphylaxis, are preferably studied with multiplex assays. 87 Multiplex assays performed early in life seem to be also useful for predicting the risk of developing allergic symptoms in later life. [88][89][90] Clinicians should always be adequately trained, familiar with the main allergen protein families, and aware of the characteristics of the PAMD@ assays.…”

Section: Patients Most Likely To Benefit From Pamd@mentioning

confidence: 99%

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ansotegui¹,

Melioli²,

Canonica³

et al. 2020

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.

show abstract

Section: Patients Most Likely To Benefit From Pamd@mentioning

confidence: 99%

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ansotegui¹,

Melioli²,

Canonica³

et al. 2020

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…A sensibilização a múltiplos alimentos é frequente em pacientes com DA que apresentem altos valores de IgE sérica 33 . Entretanto, é relevante frisar que a detecção de IgE específica para um alimento ou seus componentes não implica necessariamente em representatividade clínica, que deve ser confirmada por meio de eliminação e reexposição ao(s) alergeno(s) em questão 32,34 . A avaliação etiológica da DA, doença com ciclos de melhora e de piora relacionados a uma grande multiplicidade de fatores, pode ser tarefa bastante difícil 35,36 .…”

Section: Dermatite Atópicaunclassified

“…O diagnóstico molecular é capaz de identificar sensibilização a alérgenos naturais ou recombinantes, e permite diferenciar entre alergia genuína ou reatividade cruzada em pacientes polissensibilizados, orientando o tratamento direcionado a alérgenos e identificando o risco de anafilaxia a algumas proteínas alimentares 24,34 . Exemplo disto é a sensibilização ao ovo, bastante comum em pacientes com DA, estimada em torno de 35 a 73%.…”

Section: Dermatite Atópicaunclassified

Aplicações práticas de uma plataforma multiplex para detecção de IgE específica por componentes alergênicos em doenças alérgicas

Cocco¹,

Neto²,

Aun³

et al. 2018

Arquivos De Asma, Alergia E Imunologia

View full text Add to dashboard Cite

show abstract

“…Initially, natural allergen extract–based diagnostic tests appeared less costly. However, the new multiplex tests using comprehensive panels of allergen molecules can resolve complicated cases of polysensitization more quickly56 and allow the selection of AIT more correctly than allergen extract–based tests 57,58. Therefore, recombinant allergen–based diagnostic tests seem to be more cost-effective than allergen extracts, and the advantages of molecular-based allergy diagnostics have been also recognized by the World Allergy Organization in a position paper 59.…”

Section: Manufacturing Of Single Recombinant or Natural Allergens Andmentioning

confidence: 99%

Single recombinant and purified major allergens and peptides

Curin

Garib

Valenta

2017

Annals of Allergy, Asthma & Immunology

Self Cite

View full text Add to dashboard Cite

During the last 25 years more than several hundred allergen sequences were determined, which led to a production of recombinant allergens that mimic biochemically and immunologically their natural counterparts. Especially in Europe, recombinant allergens are increasingly replacing allergen extracts in diagnosis of allergy. Despite many challenges, such as high cost of clinical trials and regulative issues, allergy vaccines based on recombinant allergens and peptides are being developed and will likely soon be available on the market.

show abstract

Microarray‐based IgE serology improves management of severe atopic dermatitis in two children

Cited by 19 publications

References 10 publications

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Aplicações práticas de uma plataforma multiplex para detecção de IgE específica por componentes alergênicos em doenças alérgicas

Single recombinant and purified major allergens and peptides

Contact Info

Product

Resources

About